Literature DB >> 20236926

Studies on the role of acid sphingomyelinase and ceramide in the regulation of tumor necrosis factor alpha (TNFalpha)-converting enzyme activity and TNFalpha secretion in macrophages.

Krasimira A Rozenova1, Gergana M Deevska, Alexander A Karakashian, Mariana N Nikolova-Karakashian.   

Abstract

Acid sphingomyelinase (ASMase) has been proposed to mediate lipopolysaccharide (LPS) signaling in various cell types. This study shows that ASMase is a negative regulator of LPS-induced tumor necrosis factor alpha (TNFalpha) secretion in macrophages. ASMase-deficient (asm(-/-)) mice and isolated peritoneal macrophages produce severalfold more TNFalpha than their wild-type (asm(+/+)) counterparts when stimulated with LPS, whereas the addition of exogenous ceramides or sphingomyelinase reduces the differences. The underlying mechanism for these effects is not transcriptional but post-translational. The TNFalpha-converting enzyme (TACE) catalyzes the maturation of the 26-kDa precursor (pro-TNFalpha) to an active 17-kDa form (soluble (s)TNFalpha). In mouse peritoneal macrophages, the activity of TACE was the rate-limiting factor regulating TNFalpha production. A substantial portion of the translated pro-TNFalpha was not processed to sTNFalpha; instead, it was rapidly internalized and degraded in the lysosomes. TACE activity was 2-3-fold higher in asm(-/-) macrophages as compared with asm(+/+) macrophages and was suppressed when cells were treated with exogenous ceramide and sphingomyelinase. Indirect immunofluorescence analyses revealed distinct TNFalpha-positive structures in the close vicinity of the plasma membrane in asm(-/-) but not in asm(+/+) macrophages. asm(-/-) cells also had a higher number of early endosomal antigen 1-positive early endosomes. Experiments that involved inhibitors of TACE, endocytosis, and lysosomal proteolysis suggest that in the asm(-/-) cells a significant portion of pro-TNFalpha was sequestered within the early endosomes, and instead of undergoing lysosomal proteolysis, it was recycled to the plasma membrane and processed to sTNFalpha.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20236926      PMCID: PMC2898350          DOI: 10.1074/jbc.M109.080671

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  IFN-gamma inhibits the suppressive effects of PGE2 on the production of tumor necrosis factor-alpha by mouse macrophages.

Authors:  J G Kim; Y S Hahn
Journal:  Immunol Invest       Date:  2000-08       Impact factor: 3.657

2.  CD95 signaling via ceramide-rich membrane rafts.

Authors:  H Grassme; A Jekle; A Riehle; H Schwarz; J Berger; K Sandhoff; R Kolesnick; E Gulbins
Journal:  J Biol Chem       Date:  2001-03-12       Impact factor: 5.157

3.  Endocytosis of uncleaved tumor necrosis factor-alpha in macrophages.

Authors:  W Shurety; J K Pagan; J B Prins; J L Stow
Journal:  Lab Invest       Date:  2001-01       Impact factor: 5.662

4.  Stimulation-induced down-regulation of tumor necrosis factor-alpha converting enzyme.

Authors:  J R Doedens; R A Black
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

5.  Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis.

Authors:  M L Wong; B Xie; N Beatini; P Phu; S Marathe; A Johns; P W Gold; E Hirsch; K J Williams; J Licinio; I Tabas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

6.  A lipopolysaccharide-specific enhancer complex involving Ets, Elk-1, Sp1, and CREB binding protein and p300 is recruited to the tumor necrosis factor alpha promoter in vivo.

Authors:  E Y Tsai; J V Falvo; A V Tsytsykova; A K Barczak; A M Reimold; L H Glimcher; M J Fenton; D C Gordon; I F Dunn; A E Goldfeld
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

7.  Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion.

Authors:  K A Solomon; N Pesti; G Wu; R C Newton
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

8.  Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs.

Authors:  María Victoria Gómez-Gaviro; Isidoro González-Alvaro; Carmen Domínguez-Jiménez; Jacques Peschon; Roy A Black; Francisco Sánchez-Madrid; Federico Díaz-González
Journal:  J Biol Chem       Date:  2002-07-29       Impact factor: 5.157

9.  Post-transcriptional regulation of TNF-alpha during in vitro differentiation of human monocytes/macrophages in primary culture.

Authors:  Simon MacKenzie; Neus Fernàndez-Troy; Enric Espel
Journal:  J Leukoc Biol       Date:  2002-06       Impact factor: 4.962

10.  The proximal promoter region is essential for lipopolysaccharide induction and cyclic AMP inhibition of mouse tumor necrosis factor-alpha.

Authors:  Phyllis M O'Donnell; Steven M Taffet
Journal:  J Interferon Cytokine Res       Date:  2002-05       Impact factor: 2.607

View more
  28 in total

1.  Defining a role for acid sphingomyelinase in the p38/interleukin-6 pathway.

Authors:  David M Perry; Benjamin Newcomb; Mohamad Adada; Bill X Wu; Patrick Roddy; Kazuyuki Kitatani; Leah Siskind; Lina M Obeid; Yusuf A Hannun
Journal:  J Biol Chem       Date:  2014-06-20       Impact factor: 5.157

2.  Reactive oxygen species and p38 mitogen-activated protein kinase mediate tumor necrosis factor α-converting enzyme (TACE/ADAM-17) activation in primary human monocytes.

Authors:  Alasdair J Scott; Kieran P O'Dea; David O'Callaghan; Lynn Williams; Justina O Dokpesi; Louise Tatton; Jonathan M Handy; Philip J Hogg; Masao Takata
Journal:  J Biol Chem       Date:  2011-08-24       Impact factor: 5.157

Review 3.  Ceramides as modulators of cellular and whole-body metabolism.

Authors:  Benjamin T Bikman; Scott A Summers
Journal:  J Clin Invest       Date:  2011-11-01       Impact factor: 14.808

4.  Loss of TIMP3 selectively exacerbates diabetic nephropathy.

Authors:  Ratnadeep Basu; Jiwon Lee; Zuocheng Wang; Vaibhav B Patel; Dong Fan; Subhash K Das; George C Liu; Rohan John; James W Scholey; Gavin Y Oudit; Zamaneh Kassiri
Journal:  Am J Physiol Renal Physiol       Date:  2012-08-15

5.  Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway.

Authors:  L Bizzozero; D Cazzato; D Cervia; E Assi; F Simbari; F Pagni; C De Palma; A Monno; C Verdelli; P R Querini; V Russo; E Clementi; C Perrotta
Journal:  Cell Death Differ       Date:  2013-12-06       Impact factor: 15.828

Review 6.  Acid sphingomyelinase in macrophage biology.

Authors:  Jean-Philip Truman; Mohammed M Al Gadban; Kent J Smith; Samar M Hammad
Journal:  Cell Mol Life Sci       Date:  2011-05-02       Impact factor: 9.261

7.  Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidase.

Authors:  Russell W Jenkins; Christopher J Clarke; Daniel Canals; Ashley J Snider; Christopher R Gault; Linda Heffernan-Stroud; Bill X Wu; Fabio Simbari; Patrick Roddy; Kazuyuki Kitatani; Lina M Obeid; Yusuf A Hannun
Journal:  J Biol Chem       Date:  2011-02-18       Impact factor: 5.157

8.  A Novel Combination of Fruits and Vegetables Prevents Diet-Induced Hepatic Steatosis and Metabolic Dysfunction in Mice.

Authors:  Weimin Guo; Dayong Wu; Maria C Dao; Lijun Li; Erin D Lewis; Edwin F Ortega; Heesun Eom; Michael Thomas; Mariana Nikolova-Karakashian; Mohsen Meydani; Simin N Meydani
Journal:  J Nutr       Date:  2020-11-19       Impact factor: 4.798

9.  Ceramide 1-phosphate mediates endothelial cell invasion via the annexin a2-p11 heterotetrameric protein complex.

Authors:  Jody L Hankins; Katherine E Ward; Sam S Linton; Brian M Barth; Robert V Stahelin; Todd E Fox; Mark Kester
Journal:  J Biol Chem       Date:  2013-05-21       Impact factor: 5.157

Review 10.  The role of ceramide-1-phosphate in biological functions.

Authors:  L Alexis Hoeferlin; Dayanjan S Wijesinghe; Charles E Chalfant
Journal:  Handb Exp Pharmacol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.